A Hong Kong biotech company said its therapeutic HIV vaccine showed “promising” results in a recent clinical trial, taking it ...

ACTG is honored to share these important findings with the many global stakeholders who are gathered in Indonesia at the Union Conference,” said ACTG Chair Judith Currier, M.D., M.Sc., University of ...

While PAH can occur due to unknow reasons (what physicians call idiopathic), some common causes include: Connective tissue ...

or HIV, spread through sexual contact and other exchanges of bodily fluids. There was no cure and no treatment. People with ...

And the risk of this happening increases with age (especially after 50 years), a compromised immune system (e.g. in HIV and ...

Gilead Sciences, Inc. today presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE 2 trial (NCT04925752), which is studying twice-yearly lenacapavir, the company's ...

From Bettina Bauer, Vice President, US HIV Treatment and Prevention, Gilead Sciences In 2022, there were up to 1.2 million ...

Highly effective treatments for HIV have existed since the mid-1990s. But while these treatments keep people healthy, we do not yet have a safe and scalable way to completely rid the body of the virus ...

HONG KONG SAR - Media OutReach Newswire – 12 November 2024 - Immuno Cure BioTech (" Immuno Cure "), a clinical-stage ...

After being launched as a pilot project with clinics in Igatpuri and Jawhar, the initiative expanded significantly during the ...

Gilead Sciences, Inc. today announced the presentation of new research data from its innovative HIV treatment portfolio and pipeline, including a broad range of data on investigational and marketed ...

Immuno Cure Biotech Presents Promising Results on Phase I Clinical Trial of a Therapeutic HIV DNA Vaccine Media OutReach ...